Medical Cannabis
Characteristics of Medicinal Cannabis

The Cannabis plant contains active chemical compounds that can act on specific receptors in the human body. Currently there are just over 100 cannabinoids that have been discovered in the cannabis plant. The most researched are THC and CBD. At present, the vast majority of medicinal cannabis products focus on these two central active ingredients.

There is clinical evidence of the therapeutic properties of cannabinoids for the suppression of nausea and vomiting in chemotherapy treatments, appetite stimulation or inhibition of neuropathic pain, spasticity and anxiety, although there is also pre-clinical evidence of their neuroprotective, anti-tumour and anti-inflammatory uses. Some cannabinoids have been shown in preclinical models to have antipsychotic, anxiolytic and anticonvulsant effects in patients, as well as exhibiting antioxidant properties.


Other families of chemical compounds with therapeutic potential are produced by C. sativa, including terpenoids, volatile compounds responsible for cannabis’ organoleptic properties.
In addition to more than 100 cannabinoids and terpenoids, the plant produces other families of compounds (flavonoids, alkaloids, and phytosterols) whose therapeutic potential is being investigated by a variety of research groups.



Therapeutic properties with scientific evidence
  • Appetite enhancement
  • Anti-inflammatory
  • Neuroprotective
  • Antioxidant
  • Muscle relaxant
  • Rduction of nausea
  • Analgesic
  • Antitumour



  • Treatment of diseases related to muscle spasticity such as Parkinson’s and Multiple Sclerosis.
  • Chronic neuropathic pain, pain derived from metastasis and osteoarthritis.
  • Better tolerance to chemotherapy treatments
  • Anti-tumour treatments


Therapeutic properties with scientific evidence
  • Analgesic
  • Neuroprotective
  • Anticonvulsant
  • Antioxidant
  • Anti-inflammatory
  • Antiemetic
  • Antitumour
  • Anxiolytic
  • Antipsychotic
  • Chronic inflammatory diseases
  • Anxiety
  • Epilepsy
  • Anti-tumour treatments
  • Neurodegenerative diseases
  • Addictions
  • Psychosis
  • Autism spectrum disorders
  • Chemotherapy accompaniment
Variety A type

Is a variety with indica dominance, it is a phenotype with excellent agronomic behaviour, with vigorous growth and medium internodal distances. The cultivation cycle lasts approximately 60 days and produces 310 gr. of compact flowers per plant with a high THC content and a superb post-harvest aptitude.




Variety B Type

Comes from a specific cross developed for Mediterranean climates, it is a plant variety of medium structure and an intense dark green colour, it has a good lateral branching and bushy appearance. Sativa-dominant, it has seven leaflets and a wide internodal distance, generating compact flowers with a high THC content and a significant THCV content. We manage this variety to obtain around 350 grams per plant.

Variety C type

Is a cultivar with a balanced THC and CBD content. With an indica dominance, it has a small size with a large number of side branches, which well managed is capable of producing more than 380 grams per plant despite being very demanding in growing conditions. Its compact flowers, long trichomes and very few bracts allow a shorter drying process.

Variety D type

is our CBD genetics, which is able to express almost 2% of CBDV and a predominance of limonene and myrcene in its terpene profile. It is medium-sized, deep green in colour and has relatively short internodal distances compared to other varieties. Its flowers are medium-sized, reach the end of the cycle after 80 days and it is an ideal variety for extraction.

Variety 5

Forbidden Dream is a sativa dominant hybrid crossing Forbidden Fruit and Geist OG, with a total THC content of 22% and 4.63% terpenes, Myrcene Limonene Caryophyllene dominant. The genetic exhibits citric, acrid and gassy overtones backed by sharp pine, orange peel and black pepper hints.

Click here for a varietal sheet of forbidden dream




We develop 100% tailored solutions





Main areas of medical application
Tratamiento del dolor
Pain treatment

There is a growing body of clinical and preclinical scientific evidence on the benefits of the use of cannabinoids in pain treatment, especially in neuropathic pain, which is pain generated directly in the nervous system.





The use of cannabinoids by oncology patients is generally aimed at achieving an anti-tumour response or alleviating the side effects of certain therapies they are facing. It is common for these two situations to occur simultaneously.


Studies aimed at studying the effects of cannabinoids on neurodegenerative diseases such as Alzheimer’s, Parkinson’s or Lateral Sclerosis are leading promising advances in research groups worldwide in this field, working to delay the symptoms and quality of life of patients.

Scientific Advisory Board

Dr. Xavier Nadal holds a BSc in Biology (in 2003) from the Universitat de Barcelona (UB), a MSc in Pharmacology (in 2006) and a PhD in Health and Life Sciences (in 2011) from the Universitat Pompeu Fabra (UPF). His PhD research in the Neuropharmacology laboratory at UPF focused on the role of the endocannabinoid and opioid systems in the regulation of neuropathic pain. From 2011 to 2018, he was head of the R&D-Extraction Department at Phytoplant Research, where he developed 2 patent families for the purification of cannabinoids by direct crystallization of extracts or by liquid-liquid chromatography. Throughout his academic and professional career Dr. Xavier Nadal has published several scientific articles and book chapters on the endocannabinoid system, focusing on the applications and mechanisms of action of phytocannabinoids.




Consejo científico asesor
Nombre: Dr. Xavier Nadal Roure
Cargo: Director
Empresa: EthnoPhytoTech Research & Consulting

Originally from Michigan, and after earning a BSc and MSc in Agronomy, he received his PhD in Plant Biology from the University of California, Davis in 2008. He has worked in private industry in France and Spain as a plant breeder for Syngenta, and for the past 10 years as a researcher focusing on molecular breeding and plant genomics at the Centre for Research in Agricultural Genomics (CRAG) and the Institute for Research and Technology in Agri-Food (IRTA) in Barcelona. For the last five years he has led the CRAG/IRTA partnership with an US company, based in Colorado (USA), to apply genetic marker technology to cannabis breeding under the first cultivation authorization granted to a Public Research Organization by AEMPS in Spain.




Jason Argyris
Nombre: Dr. Jason Argyris
Cargo: Cannabis Breeding Researcher
Empresa: CRAG

Professor of Soil Science and Agricultural Chemistry at the Faculty of Science at the University of Extremadura. PhD in Biological Sciences. Visiting Professor at the Soil and Water Science Department of the University of Florida, USA.
He is the director or co-director of 11 PhD Theses, several of them with International Mention and Extraordinary Doctorate Award, as well as numerous Bachelor’s Theses, degree and Master’s theses in the experimental R+D+I modality.


Coordinator and founder in 1998 of the Research Group Management, conservation and recovery of soils, water and sediments (GORSAS). His research interests are in circular economy, sustainability of primary production systems, food safety and quality, adaptation to climate change, and efficient use of resources. He has participated in 34 international, national and regional research projects, author of more than 60 indexed articles in the areas of Agricultural and Environmental Sciences, and numerous participations in communications and extension activities in projects with cooperatives and companies, public bodies and administrations.



Antonio López Pineiro
Nombre: Dr. Antonio López Piñeiro
Cargo: Catedrático
Empresa: Universidad de Extremadura

Holds a degree in Agricultural Engineering from the Instituto Superior de Agronomia, where he graduated in 1992 and where he completed a master’s degree in Plant Nutrition, Soils and Fertilisation. He obtained his PhD at the UEX.

He has published about 4 dozen scientific articles in indexed journals, in addition to several other scientific and knowledge transfer publications in national and international journals. He participated or coordinated more than 2 dozen national and international research projects. He is a professor at the Polytechnic Institute of Portalegre since 1996, where he has been President of the Pedagogical Council and Director of the Escola Superior Agrária de Elvas.



Jose Manuel Rato Nunes
Nombre: Dr. José Manuel Rato Nunes
Cargo: President of the Pedagogical Council
Empresa: Escola Superior Agrária de Elvas
We bring new medicinal cannabis formulations to the Pharmaceutical Industry